• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

    4/30/25 8:00:00 AM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email

    It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction

    Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates

    Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") related to its proposed merger (the "Merger") with Akoya Biosciences ("Akoya") (NASDAQ:AKYA):

    "Quanterix's decision to press on with the Merger in the face of significant public shareholder opposition is bad enough. What is even more egregious is the fact that the Company will no longer provide shareholders with the opportunity to vote on the Merger. This shocking disenfranchisement indicates a blatant disregard for the will of shareholders and a complete lack of accountability on the part of the Company's Board of Directors – especially since vote reports showed the proposal for the Merger losing by a nearly 3-1 margin.

    In its press release yesterday, Quanterix Chief Executive Officer Masoud Toloue stated that "the strategic merits of the transaction remain strong."1 Unfortunately for Dr. Toloue, the steep decline in Quanterix's stock price and enterprise value – which are down 48% and over 100%, respectively, since the Merger was announced, tell a different story.2 If the Company truly believes in the merits of the transaction, why is it afraid to let shareholders vote on it?

    We believe that it is no longer possible to trust a Board that negotiated such a value-destructive transaction in the first place and that has now decided to ignore the concerns of major shareholders. Quanterix's directors have proven themselves unable to represent the best interests of shareholders. This situation makes the need for boardroom change even more pressing, and we will continue our efforts to elect the three highly qualified individuals we have nominated to the Board at this year's Annual Meeting. We look forward to communicating further in the weeks to come."

    About Kent Lake

    Kent Lake Partners LP is an investment fund founded by Ben Natter in 2019 with a focus on small and mid-capitalization public equities, particularly in the healthcare space. Mr. Natter has over a decade of successful public healthcare equity investing experience.

    Certain Information Concerning the Participants

    Kent Lake Partners LP ("Kent Lake Partners"), together with the other Participants (as defined below), intends to file a preliminary proxy statement and an accompanying GOLD universal proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for, among other matters, the election of its slate of highly-qualified director nominees at the 2025 annual meeting of stockholders of Quanterix Corporation, a Delaware corporation (the "Company").

    KENT LAKE PARTNERS STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING ITS GOLD PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.

    The participants in the proxy solicitation are currently anticipated to be Kent Lake Partners, Kent Lake PR LLC ("Kent Lake PR") and Benjamin Natter (collectively, the "Kent Lake Parties"); and Alexander G. Dickinson, Bruce Felt and Hakan Sakul (the "Kent Lake Nominees" and collectively with the Kent Lake Parties, the "Participants").

    As of the date hereof, Kent Lake Partners directly beneficially owned 2,926,865 shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock"). Kent Lake PR, as the investment adviser and as the general partner to Kent Lake Partners, may be deemed to beneficially own the 2,926,865 shares of Common Stock beneficially owned by Kent Lake Partners. Mr. Natter, as the Managing Member of Kent Lake PR, may be deemed to beneficially own the 2,926,865 shares of Common Stock beneficially owned by Kent Lake Partners. None of the Kent Lake Nominees beneficially own any shares of Common Stock. All of the foregoing information is as of the date hereof unless otherwise disclosed.

    1 Company press release dated April 29, 2025.

    2 Figures from January 8, 2025, the last trading day before the announcement of the Merger, through market close on April 29, 2025.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250430231448/en/

    Investor Contacts

    Ben Natter, 415-237-0007

    info@kentlakecap.com

    Saratoga Proxy Consulting LLC

    John Ferguson / Ann Marie Mellone

    212-257-1311 / 888-368-0379

    info@saratogaproxy.com

    Media Contact

    Longacre Square Partners

    Joe Germani / Kendall Heebink

    KentLake@longacresquarepartners.com

    Get the next $AKYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKYA
    $QTRX

    CompanyDatePrice TargetRatingAnalyst
    Quanterix Corporation
    $QTRX
    8/11/2025$5.00Buy → Hold
    Canaccord Genuity
    Akoya BioSciences Inc.
    $AKYA
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    Akoya BioSciences Inc.
    $AKYA
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    Akoya BioSciences Inc.
    $AKYA
    8/6/2024Buy → Neutral
    BTIG Research
    Akoya BioSciences Inc.
    $AKYA
    8/6/2024Overweight → Neutral
    JP Morgan
    Akoya BioSciences Inc.
    $AKYA
    6/21/2024$7.50Buy
    Craig Hallum
    Quanterix Corporation
    $QTRX
    2/1/2024$30.00Sector Outperform
    Scotiabank
    Akoya BioSciences Inc.
    $AKYA
    12/14/2023Neutral
    Guggenheim
    More analyst ratings

    $AKYA
    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

    Strategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quante

    6/4/26 8:02:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Company and its strategic priorities. The Company is also scheduling one-on-one investor meetings at the event. Webcast Information The live webcast presentation can be accessed from the Investor Relations section of the company's webs

    6/3/26 8:01:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an inducement grant (the "Inducement Grant") was made to Anthony Catalano in connection with the commencement of his employment as the Chief Operating Officer of the Company. The Inducement Grant consists of restricted stock units ("RSUs") covering 141,330 shares of Quanterix common stock. The RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Catalano's continued employment with the Company or one of its subsidiaries throu

    5/26/26 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    $QTRX
    SEC Filings

    View All

    Quanterix Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Quanterix Corp (0001503274) (Filer)

    5/26/26 5:25:36 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Quanterix Corporation

    SCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)

    5/15/26 4:06:24 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Quanterix Corporation

    SCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)

    5/15/26 10:36:24 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quanterix downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $5.00

    8/11/25 9:55:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

    11/15/24 8:33:16 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Akoya Biosciences downgraded by Morgan Stanley

    Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

    8/6/24 12:17:30 PM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.27% to 33,795 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/1/26 4:06:29 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Sriram Vandana converted options into 1,833 shares and covered exercise/tax liability with 548 shares, increasing direct ownership by 4% to 29,998 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    5/18/26 5:34:46 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 33,704 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    5/18/26 5:34:23 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sriram Vandana bought $19,878 worth of shares (4,150 units at $4.79), increasing direct ownership by 5% to 87,200 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    9/17/25 10:24:11 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/13/25 4:39:15 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/10/25 4:08:44 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    $QTRX
    Financials

    Live finance-specific insights

    View All

    Quanterix Releases Financial Results for the First Quarter of 2026

    Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. "We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition," said Everett Cunningham, President & CEO of Quanterix. "As part of this process, we are focusing our

    5/6/26 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. In conjunction with this announcement, the Company will host a conference call on May 6, 2026, at 4:30 PM ET. The dial-in number for USA & Canada

    4/24/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation Announces Date of 2026 Annual Meeting

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the "Company"), today announced that the Company's 2026 annual meeting of shareholders (the "Annual Meeting") will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company's common stock as of the close of business on April 14, 2026 will be entitled to vote at the Annual Meeting. Additional information regarding the Annual Meeting will be provided in the Company's proxy statement. Because the date of the Annual Meeting has been advanced by more than thirty (30) days from the anniversary

    3/27/26 4:00:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    $QTRX
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

    Strategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quante

    6/4/26 8:02:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $AKYA
    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

    SC 13G/A - Quanterix Corp (0001503274) (Subject)

    11/13/24 12:41:46 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

    SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

    11/4/24 7:39:24 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Akoya BioSciences Inc.

    SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

    8/28/24 10:45:17 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials